Loading...
XTAI1762
Market cap78mUSD
Dec 24, Last price  
33.15TWD
1D
0.45%
1Q
-21.91%
Jan 2017
22.55%
IPO
-47.46%
Name

Chunghwa Chemical Synthesis & Biotech Co Ltd

Chart & Performance

D1W1MN
XTAI:1762 chart
P/E
9.71
P/S
1.23
EPS
3.42
Div Yield, %
3.92%
Shrs. gr., 5y
-0.06%
Rev. gr., 5y
15.40%
Revenues
2.09b
-1.45%
1,126,848,0001,197,243,0001,200,576,0001,329,584,0001,043,480,000946,704,0001,162,211,0001,198,670,0001,168,248,0001,019,452,0001,156,642,0001,543,589,0001,934,702,0002,117,144,0002,086,440,999
Net income
265m
-43.14%
245,105,000187,004,000170,994,000175,564,00096,825,00014,592,000308,356,00060,283,00085,766,000234,251,000117,003,000531,873,000400,778,000465,865,000264,909,000
CFO
-78m
L
462,069,000275,614,000144,843,000268,465,000145,240,00023,081,00079,705,000261,313,000159,339,000234,664,000268,128,000138,235,000219,179,000733,779,000-77,503,000
Dividend
Jul 26, 20240.8 TWD/sh
Earnings
Mar 10, 2025

Profile

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and wholesale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, cardiovascular, and other products, as well as peptide drugs. The company also develops bulk pharmaceutical products, such as anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular drugs, skeletal, muscle relaxants, hypolipaemics, antineoplastic, antihyperlipedemias, and immunosuppressant products, as well as provides research and development, and contract manufacturing services to new drug developers and generic drug companies. The company was formerly known as China Chemical Synthesis Industry Co., Ltd. Chunghwa Chemical Synthesis & Biotech Co., Ltd. was founded in 1964 and is headquartered in New Taipei City, Taiwan.
URL
http://www.ccsb.com.tw/
IPO date
Dec 10, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,086,441
-1.45%
2,117,144
9.43%
1,934,702
25.34%
Cost of revenue
1,805,632
1,671,957
1,477,882
Unusual Expense (Income)
NOPBT
280,809
445,187
456,820
NOPBT Margin
13.46%
21.03%
23.61%
Operating Taxes
68,578
117,165
96,563
Tax Rate
24.42%
26.32%
21.14%
NOPAT
212,231
328,022
360,257
Net income
264,909
-43.14%
465,865
16.24%
400,778
-24.65%
Dividends
(100,828)
(100,828)
(116,340)
Dividend yield
2.25%
1.96%
2.29%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
504,645
103,824
152,535
Long-term debt
712,298
503,983
603,356
Deferred revenue
26,995
500,000
600,000
Other long-term liabilities
(500,000)
(600,000)
Net debt
(47,107)
(701,761)
(509,645)
Cash flow
Cash from operating activities
(77,503)
733,779
219,179
CAPEX
(451,551)
(376,184)
(405,453)
Cash from investing activities
(461,324)
(376,184)
(802,750)
Cash from financing activities
496,574
(253,318)
630,615
FCF
(680,090)
273,847
(188,755)
Balance
Cash
269,569
300,614
195,250
Long term investments
994,481
1,008,954
1,070,286
Excess cash
1,159,728
1,203,711
1,168,801
Stockholders' equity
2,519,689
2,859,273
2,560,528
Invested Capital
3,426,615
2,543,873
2,447,979
ROIC
7.11%
13.14%
17.08%
ROCE
5.80%
11.12%
11.81%
EV
Common stock shares outstanding
78,092
78,500
78,318
Price
57.40
-12.50%
65.60
1.08%
64.90
5.53%
Market cap
4,482,481
-12.95%
5,149,600
1.31%
5,082,838
5.51%
EV
4,435,374
4,448,025
4,573,383
EBITDA
473,814
614,236
588,813
EV/EBITDA
9.36
7.24
7.77
Interest
19,439
9,712
3,321
Interest/NOPBT
6.92%
2.18%
0.73%